ArticleBMC cancer2019
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Zongbi Yi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
25 papers cite it
this papertrialcites it